The Guardian · Oct 30, 2026
FDA removes menopause patch warnings without advisory review
The FDA removed black-box warnings from three estrogen patches used for menopause without convening an advisory committee. These warnings had flagged risks of cardiovascular disease, breast cancer, and dementia.
Why it matters: The decision affects how patients and doctors weigh risks and benefits of menopause hormone treatments.
Keep in mind: This reporting describes an FDA decision process but provides no clinical evidence about actual risks or benefits.
AI-assisted summary of the publisher’s feed. News coverage, not an independent study.
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.